Amarantus Bioscience (OTCMKTS:AMBS) & COMPASS Pathways (NASDAQ:CMPS) Financial Contrast

Amarantus Bioscience (OTCMKTS:AMBS) and COMPASS Pathways (NASDAQ:CMPS) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, dividends, profitability, analyst recommendations, institutional ownership, risk and valuation.

Valuation and Earnings

This table compares Amarantus Bioscience and COMPASS Pathways”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amarantus Bioscience	N/A	N/A	N/A	N/A	N/A
COMPASS Pathways	N/A	N/A	-$155.12 million	($2.72)	-2.65

Analyst Recommendations

This is a summary of recent ratings and target prices for Amarantus Bioscience and COMPASS Pathways, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amarantus Bioscience	0	0	0	0	0.00
COMPASS Pathways	1	1	6	0	2.63

COMPASS Pathways has a consensus target price of $15.57, suggesting a potential upside of 115.82%. Given COMPASS Pathways’ stronger consensus rating and higher possible upside, analysts plainly believe COMPASS Pathways is more favorable than Amarantus Bioscience.

Insider & Institutional Ownership

46.2% of COMPASS Pathways shares are owned by institutional investors. 10.3% of Amarantus Bioscience shares are owned by company insiders. Comparatively, 3.9% of COMPASS Pathways shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares Amarantus Bioscience and COMPASS Pathways’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Amarantus Bioscience	N/A	N/A	N/A
COMPASS Pathways	N/A	-111.18%	-56.55%

Volatility and Risk

Amarantus Bioscience has a beta of 1.59, suggesting that its share price is 59% more volatile than the S&P 500. Comparatively, COMPASS Pathways has a beta of 1.92, suggesting that its share price is 92% more volatile than the S&P 500.

Summary

COMPASS Pathways beats Amarantus Bioscience on 5 of the 8 factors compared between the two stocks.

About Amarantus Bioscience

Amarantus BioScience Holdings, Inc., a biopharmaceutical company, focuses on the development of diagnostic and therapeutic product candidates in the areas of neurology, psychiatry, ophthalmology, and regenerative medicine. The company's diagnostic products in development include the lymphocyte proliferation (LymPro) test, a diagnostic blood test for Alzheimer's disease; and MSPrecise, a proprietary DNA sequencing assay for the identification of patients with multiple sclerosis. Its therapeutic products in development comprise Eltoprazine, a small molecule drug for the treatment of Parkinson's disease Levadopa-Induced Dyskinesia and attention deficit hyperactivity disorders; and mesencephalic-astrocyte-derived neurotrophic factor for the treatment of various animal models, including retinitis pigmentosa and retinal artery occlusion. It also develops NuroPro, a neurodegenerative disease diagnostic platform with application in Parkinson's disease; BC-SeraPro, an oncology diagnostic platform with application in breast cancer; and PhenoGuard platform for neurrotrophic factor discovery. In addition, the company develops Engineered Skin Substitute (ESS), a cell therapy-based autologous skin replacement product that is in mid-stage clinical development for the treatment of life-threatening severe burns. Amarantus BioScience Holdings, Inc. has a cooperative research and development agreement with the U.S. Army Institute of Surgical Research and Rutgers University. The company was formerly known as Amarantus Bioscience, Inc. and changed its name to Amarantus BioScience Holdings, Inc. in April 2013. Amarantus BioScience Holdings, Inc. was founded in 2008 and is headquartered in New York, New York.

About COMPASS Pathways

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. COMPASS Pathways plc was incorporated in 2020 and is headquartered in London, the United Kingdom.